Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma.

Saved in:
Bibliographic Details
Title: Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma.
Authors: Yao, Yue‐Liang1,2 (AUTHOR), Wang, Yan‐Xia1 (AUTHOR), Yang, Fei‐Cheng1 (AUTHOR), Wang, Chuan1 (AUTHOR), Mao, Min1 (AUTHOR), Gai, Qu‐Jing1 (AUTHOR), He, Jiang1 (AUTHOR), Qin, Yan1 (AUTHOR), Yao, Xiao‐Xue1 (AUTHOR), Lan, Xi1 (AUTHOR), Zhu, Jiang1 (AUTHOR), Lu, Hui‐Min1 (AUTHOR), Zeng, Hui1 (AUTHOR), Yao, Xiao‐Hong1 (AUTHOR), Bian, Xiu‐Wu1 (AUTHOR), Wang, Yan1 (AUTHOR) wang_yan1977@hotmail.com
Source: CNS Neuroscience & Therapeutics. Jul2022, Vol. 28 Issue 7, p1033-1044. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17555930
DOI:10.1111/cns.13835